Insider Selling: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Insider Sells $77,664.06 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) insider Aranthan Jones II sold 7,313 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $10.62, for a total transaction of $77,664.06. Following the completion of the transaction, the insider now owns 82,687 shares in the company, valued at $878,135.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

VNDA opened at $10.08 on Friday. The stock has a market capitalization of $549.86 million, a price-to-earnings ratio of 4.71 and a beta of 0.54. The company has a fifty day moving average of $11.23 and a 200 day moving average of $11.64. Vanda Pharmaceuticals Inc. has a fifty-two week low of $7.12 and a fifty-two week high of $17.85.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. The company had revenue of $58.00 million during the quarter, compared to analysts’ expectations of $57.53 million. Vanda Pharmaceuticals had a net margin of 49.12% and a return on equity of 30.60%. On average, analysts anticipate that Vanda Pharmaceuticals Inc. will post 0.31 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Envestnet Asset Management Inc. grew its stake in Vanda Pharmaceuticals by 8.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 11,685 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 889 shares in the last quarter. Swiss National Bank grew its stake in shares of Vanda Pharmaceuticals by 1.4% in the 1st quarter. Swiss National Bank now owns 93,100 shares of the biopharmaceutical company’s stock worth $965,000 after buying an additional 1,300 shares in the last quarter. James Investment Research Inc. grew its stake in shares of Vanda Pharmaceuticals by 8.3% in the 2nd quarter. James Investment Research Inc. now owns 19,685 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 1,505 shares in the last quarter. Comerica Bank grew its stake in shares of Vanda Pharmaceuticals by 3.2% in the 1st quarter. Comerica Bank now owns 51,683 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 1,609 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of Vanda Pharmaceuticals by 25.7% in the 4th quarter. Victory Capital Management Inc. now owns 10,190 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 2,084 shares in the last quarter. 98.50% of the stock is owned by institutional investors.

Several research analysts have weighed in on VNDA shares. ValuEngine downgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, May 1st. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, June 11th. BidaskClub cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Citigroup cut shares of Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $14.00 price objective for the company. in a research note on Tuesday, June 9th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $15.40.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Article: How the Consumer Price Index (CPI) is calculated?

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.